Trial Profile
A Phase 1 Multi-Center, Open-Label, Dose-Escalation Study to Determine the Pharmacokinetics and Safety of Pomalidomide When Given in Combination With Low Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma and Impaired Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 May 2022
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Pharmacokinetics
- Acronyms POM Renal
- Sponsors Celgene Corporation
- 25 Apr 2022 Status changed from active, no longer recruiting to completed.
- 26 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Mar 2017 Planned End Date changed from 1 Jun 2021 to 11 Jun 2021.